EBERS normothermic perfusion system was tested at the Liver Disease University Hospital in Wuhan (China) last October 15th to 21st. Five perfusion experiments were completed in whichg pig liver subjected to 30 minutes of warm ischaemia were perfused in our system in order to improve.
Last October the 10th, EBERS signed a distribution agreement in Japan with the firm AR Brown (http://www.arbrown.com/english/). AR Brown is a leading Japanese company with commercial activity in a variety of sectors including chemicals, pharmaceuticals, automobile, aerospace and biotechnology. With this new agreement, EBERS gains access to the thriving regenerative medicine market in Japan.
The World Congress of the TERMIS society has taken place in Kyoto, Japan on September 4-7. EBERS has participated as exhibitor in the commercial exhibition of the conference and has successfully introduced its new NORMOPERF technology to renowned researchers and clinical doctors in the transplantation and tissue engineering field. Furthermore, Dr. Pedro Moreo, CEO of EBERS, has held meeting with several local companies with the goal of exploring further commercial agreements in the Japanese market.
Last October the 21st, Víctor Alastrué (CTO) participated it the regional organ donation meeting organized by Alcer Navarra association that took place in Pamplona. Víctor spoke about innovative strategies for organ preservation and shared the forum with responsibles of the local health and organ donation systems, urologists, nephrologists and pantients. The meeting was extremelly illustrative and served to give a 360 degrees perspective of the current status of the organ donation system both at regional and national levels. Not only scientific but also logistic, organizational, economical and human aspects of kidney transplantation procedure were discussed in a participative and friendly atmosphere.
 |
 |
The congress of the European Society for Artificial Organs (ESAO) has taken place in Madrid, Spain on September 12-15. EBERS has participated as exhibitor in the commercial exhibition of the conference and has successfully introduced its new NORMOPERF technology to renowned researchers and clinical doctors in the transplantation field.
 |
 |